Tumor-infiltrating dendritic cells (TID) have an ambivalent role in regulation of tumor regression or growth. However, their precise natures and molecular mechanisms have not been elucidated. In this study, we studied TIDs recruited in progressive P815 and regressive P198 tumors of the same origin. Our data showed that P815 tumors contained CD4 + 8 + and CD4 
. The three populations are derived from discrete developmental streams (2) , are located in the T cell areas as well as the marginal zones of lymph nodes, and can stimulate allogeneic T cell responses in vitro (3, 4 (6) and prolong the survival of heart allografts (7). The reasons for the different (i.e., immunogenic versus tolerogenic) results observed using the different dendritic cell subsets are at present unclear.
The repertoire of chemokines and cytokines at tumor sites is a critical determinant for successful immune responses against tumors. In general, tumor-derived chemokines are able to chemoattract various leukocytes including dendritic cells, lymphocytes, and granulocytes infiltrating into tumors (8, 9) . Among them, the tumor-infiltrating dendritic cells (TID) represent a major component of the lymphoreticular infiltrates of tumors (8) . Originally, TIDs were hypothesized to be the cells responsible for mediating tumor destruction. Many studies have associated the infiltration of tumors by dendritic cells with a favorable prognosis for cancer patients (10, 11) . TIDs activated by cytokines or chemicals facilitated tumor regression in animal tumor models (12) (13) (14) . However, others showed that TIDs were associated with poor prognosis (15) , promoted tumor growth (3, 16) , and had suppressive effects leading to tumor progression (17, 18) . Therefore, the role of TIDs in tumor immunity still remains controversial with the possibility that distinct subsets of TIDs may either aid tumor destruction or foster tumor growth.
The experimental progressive/regressive tumor cell system has been extensively used to determine the precise nature of the cells involved in progressive and regressive rat tumors (19, 20) . In this study, we selected two mouse tumor cell lines, a progressive tumor cell line, P815, and a regressive tumor cell line, P198, which is a derivative of P815 line through in vitro drug-induced mutagenesis (21, 22) . These two cell lines expressing tumor-associated antigen P1A constitutively differ in immunogenicity and tumorigenicity in syngeneic hosts. The progressive line P815 gives rise to progressive and lethal tumors, whereas the regressive line P198 yields spontaneously regressive tumors due to CTL-mediated immune responses. Therefore, this experimental P815/P198 cell system provides a well-suited model to determine the precise nature of TIDs recruited in progressive and regressive tumors. Based upon this mouse tumor model, TIDs purified from P815 and P198 tumors were phenotypically and functionally characterized. We then further investigated their functional effects in stimulation of T cells in vitro and antitumor immunity in vivo. À/À knock-out mice on H-2K d background were obtained from Jackson Laboratories (Bar Harbor, ME). All mice were housed in the animal facility of the Saskatoon Cancer Center; all animal experiments were carried out according to the guidelines of the Canadian Council for Animal Care.
Tumor-infiltrating dendritic cells and tumor-infiltrating dendritic cell subset preparation. DBA/2 mice were s.c. injected in their right thighs with 0.5 Â 10 6 P815 and P198 tumor cells, respectively. Tumors were removed when they reached f6 mm in diameter. Tumor tissues were cut into small fragments and incubated in DMEM containing 1 mg/mL collagenase (4 mL per gram of tumor tissue; Worthington Biochemical Corp., Lakewood, NJ) at 37jC for 45 to 60 minutes. Single cell suspension was prepared by pressing the digested tumor tissues through a stainless mesh. Dead cells were removed by Ficoll-Paque density gradients. The tumor cells were first removed by incubation of cell samples in anti-P1A antibody-coated plate at room temperature for 1 hour (23). TIDs were then purified from the nonadherent cells by using anti-CD11c microbeads (Miltenyi Biotech, Auburn, CA) according to the manufacturer's instructions. After overnight culture in DMEM plus 10% FCS, IL-4 and granulocyte macrophage colony-stimulating factor (15-20 ng/mL), these purified CD11c + TIDs were harvested. For TID subset purification, these TIDs were first stained with FITC-anti-CD4 and phycoerythrin-anti-CD8 antibodies and then analyzed by flow cytometry. P198 CD4 + Tumor lysate pulsing. P185 tumor lysates were prepared as previously described (24) . Briefly, P815 cells were resuspended in extraction buffer containing 0.01 mol/L Tris-HCl (pH 7.2) and 0.2 mmol/L CaCl 2 (10 mL per gram of tumor cells) and homogenized for 2 minutes on ice using a Silverson homogenizer. Cell extracts were harvested by centrifugation at 1,000 Â g for 5 minutes to remove cellular debris. For tumor lysate pulsing, 5 to 10 Â 10 6 TID subsets were pulsed with P815 tumor lysate at a ratio of 3:1 (three tumor cell lysates per dendritic cell) in AIM-V medium (Life Technologies) plus granulocyte macrophage colony-stimulating factor (15-20 ng/mL) at 37jC for overnight.
Regional lymph node T cell preparation. To examine the CD4 + T cell response, regional lymph nodes of mice s.c. immunized with 1 Â 10 6 tumor lysate-pulsed TID subsets were harvested 5 days after the immunization for cytokine secretion analysis (25) . To block the transforming growth factor-h (TGF-h) effect of CD4 per mouse) 1 day before and 2 days after the immunization for a total of two times. Briefly, cell suspensions were prepared from regional lymph nodes of immunized mice 5 days after the immunization. T cells were obtained by passage of lymph node cell suspensions through nylon wool columns. The CD4 + lymph node T cells were further purified by using anti-CD4 microbeads (Miltenyi Biotech).
Immunophenotypic analysis. For phenotypic analysis of tumor cells and TIDs, these cells were stained with a panel of biotin-conjugated antibodies (each, 5 Ag/mL), respectively, followed with FITC-conjugated avidin (1:100). Isotype-matched biotin-conjugated antibodies were used as controls. For phenotypic analysis of dendritic cell subsets, the purified TID subsets were cultured overnight and then stained with FITC-conjugated anti-CD11c, CD54, CD80, B220, and Gr1 antibodies, respectively, and analyzed by flow cytometry.
Cytokine secretion. For assessment of cytokine production, TID subsets were cultured in the presence of granulocyte macrophage colonystimulating factors (20 ng/mL) with or without the commonly used stimulus reagent lipopolysaccharide (1 Ag/mL; ref. 26) , whereas CD4 + T cells harvested from mice immunized with tumor lysate-pulsed TID subsets were restimulated with anti-CD3 antibodies (1 Ag/mL; ref. 27). After 1 day, the supernatants were assayed for IFN-g, IL-4, IL-6, IL-10, IL-12, TNF-a, and TGF-h using ELISA kits (R&D Systems; ref. 28) .
Mixed lymphocyte reaction. Primary mixed lymphocyte reactions were done as previously described (26) . Briefly, graded doses of irradiated (2,000 rad) TIDs or TID subsets starting at 1 Â 10 5 cells per well were cocultured in 96-well plates with constant numbers (2 Â 10 5 per well) of allogeneic T cells of C57BL/6 mice. After 2 days, T cell proliferation was measured using an overnight [ Cytotoxicity assays. To test TID cytotoxicity, TID 815 and TID 198 were used as effector cells, whereas 51 Cr-labeled P815, P198 and L1210 tumor cells were used as target cells. For investigating the killing mechanisms, TID subsets were assayed for their capacities to kill the tumor target cells in presence of the nitric oxide production inhibitor N G -methyl-L-arginine (1 mmol/L) or anti-TNF-a antibodies (5 Ag/mL; ref. 29) . To test CTL cytotoxicity, splenic lymphocytes from mice immunized with tumor lysatepulsed TID subsets were cocultured with irradiated (2,000 rad) P815 tumor cells for 3 days (24) . CTLs were harvested and used as effector cells, whereas 51 Cr-labeled P815, P198, and L1210 tumor cells were used as target cells. Ten thousand labeled target cells per well were mixed with effector cells at various effector/target ratios in triplicate and incubated for 24 and 6 hours for TID and CTL cytotoxicity, respectively. Percentage of specific lysis was calculated as: 100 Â [(experimental cpm À spontaneous cpm) / (maximal cpm À spontaneous cpm)]. Spontaneous counts per minute (cpm) released in the absence of effector cells was <10% of specific lysis. The maximal cpm was released by adding 1% Triton X-100 to wells in the experiment.
Animal studies. DBA/2 mice (eight each group) were s.c. injected in their right thighs with 1 Â 10 6 viable P815 and P198 tumor cells, respectively. Mice were then monitored daily for tumor progression or regression. For evaluation of TID vaccination, mice were s.c. vaccinated with 1 Â 10 6 TIDs with or without tumor lysate pulsing and TID subsets with tumor lysate pulsing, respectively. Ten days later, the mice (n = 8 per group) were challenged by s.c injection of 1 Â 10 4 P815 tumor cells. To confirm that the regulatory T cells were functional, these CD4 + Tr1 cells (2 Â 10 6 per mouse) harvested from lymph nodes of CD4 
Results
P815 and P198 are progressive and regressive tumor cell lines. Both P815 and P198 cell lines express MHC class I and P1A, but not MHC class II and CD11c (Fig. 1A) . However, P198 cell line expresses less MHC class I molecule than P815. When these two cell lines are inoculated into mice, they both initially grew into visible tumor masses (f6 mm in diameter) within 10 days. Interestingly, P815 tumors continuously grew, whereas P198 tumors started to gradually regress, leading to complete disappearance of most P198 tumors in another 2 weeks (Fig. 1B) .
Distinct tumor-infiltrating dendritic cell subsets recruited in P815 and P198 tumors. Both tumors of hematologic origin contained significant amount of TIDs. Purified TID 815 accounted for 12 F 3% of the whole cell population from P815 tumors, which is much more than V0.5% of TIDs seen in tumors of epithelial cell origin (30, 31) . This is probably because most tumors of hematologic origin tend to secrete chemokines. TID 198 from regressive P198 tumors accounted for 19 F 5% of the total cell population, reflecting the significant cellular immune responses seen in P198 tumors, which is much higher than that seen in aggressive P815 tumors.
To study the potential difference in dendritic cells recruited in tumors, TIDs were purified from P815 and P198 tumors, respectively, using anti-CD11c MACS microbeads, and then subjected to flow cytometric analysis. As shown in Fig. 2A A, P815 and P198 TIDs were stained with biotin-labeled anti-CD4, CD8, CD11b, CD11c, CD40, CD54, CD80, B220, and Gr-1 antibodies, followed with the FITC-conjugated avidin (solid lines ) and then analyzed by flow cytometry. Isotype-matched irrelevant antibodies were used as controls (dotted thin lines ). B, TIDs and flow cytometrically sorted TID subsets were stained with both FITC anti-CD4 and phycoerythrin anti-CD8 antibodies. C, purified TID subsets were cultured overnight and stained with FITC-conjugated anti-CD11c, CD54, and CD80 antibodies, respectively, and analyzed by flow cytometry. D, CD4 (Fig. 2D) , which is consistent with the previous characterization of CD4 À 8 À dendritic cells reported by MeLellan et al. (3) .
Distinct cytokine expression profiles of tumor-infiltrating dendritic cell subsets. The cytokine expression profiles of these distinct TID subsets were very different (Fig. 3) were quite similar in high-level expression (600-1,700 pg/mL) of IFN-g and IL-6 and moderate level expression (f300 pg/mL) of TNF-a, but little or no TGF-h expression. However, the cytokine expression profiles of CD4 À 8 À TID 815 did differ markedly. The CD4 À 8 À TID 815 secreted a marked level of TGF-h (500 pg/mL), but little other cytokines. All four TID subsets under lipopolysaccharide stimulation did not secrete IL-10 ( Fig. 3) and IL-12 (data not shown), which is consistent with the liver dendritic cells reported by Pillarisetty et al. (32) . In addition, all four TID subsets expressed relatively low levels of cytokines without lipopolysaccharide stimulation (data not shown).
Mixed lymphocyte reaction of tumor-infiltrating dendritic cell subsets. In general, dendritic cells are excellent antigenpresenting cells, and thus potently induce antigen-specific T cell responses against allogeneic or other antigens in vitro (28) . We found that TID 198 more efficiently activated allogeneic T cell cycling than TID 815 (Student's t test, P < 0.05) in a conventional mixed leukocyte culture (Fig. 4A) Fig. 4B and C) , whereas the CD4 À 8 À TID 815 were less effective in stimulation of allogeneic T cells (Student's t test, P < 0.01), probably due to the lower expression of CD54 and CD80 (Fig. 2C) .
Tumor-infiltrating dendritic cell cytotoxicity. Cytotoxicity assays were done in vitro to determine the direct effects of TIDs on tumor cells. Both P815 and P198 TIDs isolated 10 days after the graft in mice were strongly cytotoxic to both P815 and P198 tumor cells. The latter is more sensitive to TID killing than the former (Student's t test, P < 0.05; Fig. 5A, i and iii) . In addition, TID 198 displayed stronger cytotoxicity on both P815 and P198 tumor cells than TID 815 as TID 198 induced nearly 60% killing activity at effector/target of 50:1 on P198 cells, compared with 38% killing activity of TID815. Both TID 815 and TID 198 also showed killing activity on P1A-negative L1210 tumor cells, but in less extent, indicating that TID's killing activity is not P1A-specific. The killing activities of P815 and P198 TID subsets were similar to their unfractionated P815 and P198 TIDs (data not shown). In addition, we also investigated the killing mechanisms of TIDs. Addition of 1 mmol/L N G -methyl-L-arginine, an inhibitor of nitric oxide generation from arginine, strongly inhibited both P815 and P198 killing by P815 and P198 TIDs (Student's t test, P < 0.05), whereas TID-induced cytotoxicity was not significantly influenced by the anti-TNF-a antibodies (Student's t test, P > 0.05; Fig. 5A, ii and iv (33) . In addition, a type 1 regulatory CD4 + T cell (Tr1) population was defined, which produces high level of IL-10, but low level of IL-4, and suppresses Th1 response (33) . To study the type of CD4 + T cell immune response induced by TID subsets, mice were s.c. immunized with tumor lysate-pulsed TID subsets. Three days after immunization, CD4 + T cells were purified from regional lymph nodes and restimulated with anti-CD3 antibodies. After 1 day, the supernatants were assayed for different cytokine expressions. As shown in Fig. 6 of IFN-g (f1,300 to 2,000 pg/mL) and TNF-a (f800 to 1,200 pg/ mL), but low levels of IL-4 (f100 to 200 pg/mL) and little IL-10, which is consistent with a Th1 cell response (34) . Importantly, CD4 + T cells derived from CD4 À 8 À TID 815 subset secreted moderate levels of IFN-g (f800 pg/mL) and IL-4 (f500 pg/mL), but high levels of IL-10 (f1,300 pg/mL), which is consistent with a Tr1 cell response (34 with P815 tumor cells. As shown in Fig. 7A Cr-labeled P815, P198, and L1210 tumor cells were used as target cells. Ten thousand labeled target cells per well were mixed with effector cells at various effector/ target ratios in triplicate and incubated for 6 hours in chromium release assay. *, P < 0.05 versus cohorts of (i ) the CTLs [T (CD4 (Fig. 7D) nitrogen intermediates (35) and important cytokines (36) , and (b) the defective functions in antigen presentation (37) , costimulation (38) , and T cell stimulation (39 À 8 + dendritic cell OVA -driven antitumor immunity. Therefore, our results clearly implicated IL-10-producing Tr1 cells as central to the tolerance observed in this model system, and this is consistent with some other previous reports (43, 44) . Interestingly, it has recently been shown that the IL-10-stimulated CD11c low CD45RB high tolerogenic dendritic cells having a phenotype similar to our CD4 À 8 À dendritic cells as described in this study also induced Tr1 cell differentiation and immune tolerance in vivo (50) .
Taken together, we showed that different dendritic cell subsets were recruited into tumors. The newly identified fourth CD4 + 8 + dendritic cell subset as well as the CD4 + 8 À dendritic cell subset recruited in regressive tumors all induce Th1 and active immune response, whereas the CD4 + 8 À TIDs expressing TGF-h, which are recruited in progressive tumors, stimulate Tr1-mediated immune suppression through Tr1-secreted IL-10. Therefore, our findings will be very important in understanding the immunologic alterations in progressive and regressive tumors as well as in implications for dendritic cell-based approaches to the design of cancer vaccines.
